Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,979 | 1,013 | 51.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,288 | 48 | 48.8% |
| Education | $39.49 | 7 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $8,248 | 29 | $0 (2023) |
| ABBVIE INC. | $7,246 | 97 | $0 (2024) |
| Novo Nordisk Inc | $1,749 | 138 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,102 | 33 | $0 (2024) |
| Amgen Inc. | $1,048 | 71 | $0 (2024) |
| PFIZER INC. | $939.75 | 78 | $0 (2024) |
| Lilly USA, LLC | $856.15 | 73 | $0 (2024) |
| Amarin Pharma Inc. | $791.69 | 51 | $0 (2022) |
| Merck Sharp & Dohme LLC | $756.00 | 71 | $0 (2024) |
| GlaxoSmithKline, LLC. | $632.04 | 40 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,790 | 80 | ABBVIE INC. ($3,812) |
| 2023 | $5,612 | 128 | ABBVIE INC. ($2,764) |
| 2022 | $5,409 | 152 | Allergan, Inc. ($3,064) |
| 2021 | $5,747 | 129 | Allergan, Inc. ($4,082) |
| 2020 | $1,633 | 111 | Amarin Pharma Inc. ($419.67) |
| 2019 | $1,900 | 141 | Novo Nordisk Inc ($236.32) |
| 2018 | $2,157 | 154 | Novo Nordisk Inc ($245.23) |
| 2017 | $2,058 | 173 | Novo Nordisk Inc ($213.81) |
All Payment Transactions
1,068 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $303.00 | General |
| 11/08/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $187.00 | General |
| 10/04/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $201.00 | General |
| 09/16/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $383.00 | General |
| 08/28/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: NEUROSCIENCE | ||||||
| 08/21/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Not Applicable | ||||||
| 08/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $12.36 | General |
| Category: NEUROSCIENCE | ||||||
| 08/07/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $235.80 | General |
| 07/29/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Obesity | ||||||
| 07/25/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/22/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: Diabetes | ||||||
| 07/19/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: NEUROSCIENCE | ||||||
| 07/16/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Diabetes | ||||||
| 07/11/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $28.82 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/11/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: Diabetes Care | ||||||
| 07/10/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: Diabetes | ||||||
| 07/08/2024 | Philips North America LLC | (CK6) Holter (Device) | Food and Beverage | Cash or cash equivalent | $19.36 | General |
| Category: Medical Device | ||||||
| 07/03/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), GARDASIL 9 | Food and Beverage | In-kind items and services | $15.75 | General |
| Category: VACCINE | ||||||
| 07/02/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $337.25 | General |
| 07/02/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $2.53 | General |
| Category: NEUROSCIENCE | ||||||
| 06/28/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: Obesity | ||||||
| 06/28/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $0.68 | General |
| Category: Obesity | ||||||
| 06/28/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $0.44 | General |
| Category: Obesity | ||||||
| 06/27/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 55 | 6,656 | 9,980 | $535,140 | $265,999 |
| 2022 | 59 | 6,586 | 9,834 | $543,175 | $266,243 |
| 2021 | 58 | 6,985 | 10,076 | $521,716 | $264,217 |
| 2020 | 59 | 6,382 | 9,861 | $490,970 | $227,173 |
All Medicare Procedures & Services
231 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 420 | 420 | $66,360 | $54,138 | 81.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 486 | 651 | $104,160 | $54,024 | 51.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 1,500 | $37,500 | $27,193 | 72.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 276 | 378 | $41,580 | $22,316 | 53.7% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 541 | 804 | $32,160 | $10,502 | 32.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 616 | 1,098 | $12,370 | $9,190 | 74.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 545 | 791 | $23,730 | $8,149 | 34.3% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 29 | 29 | $9,675 | $8,043 | 83.1% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 96 | 96 | $8,692 | $6,892 | 79.3% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 277 | 323 | $16,150 | $5,289 | 32.7% |
| 82306 | Vitamin d-3 level | Office | 2023 | 159 | 179 | $15,573 | $5,141 | 33.0% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 29 | 32 | $10,304 | $4,967 | 48.2% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 27 | 27 | $6,750 | $4,456 | 66.0% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 289 | 456 | $12,768 | $4,326 | 33.9% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 39 | 39 | $17,940 | $4,235 | 23.6% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 518 | 662 | $13,240 | $4,180 | 31.6% |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | Office | 2023 | 209 | 209 | $9,614 | $3,697 | 38.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 93 | 93 | $6,324 | $3,448 | 54.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 107 | 107 | $4,240 | $3,223 | 76.0% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 52 | 54 | $6,750 | $2,507 | 37.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 263 | 265 | $21,730 | $2,340 | 10.8% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 115 | 115 | $5,970 | $2,176 | 36.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 19 | 19 | $9,500 | $1,598 | 16.8% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 76 | 84 | $3,780 | $1,242 | 32.8% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 32 | 32 | $1,130 | $953.55 | 84.4% |
About Dr. James Foster, M.D
Dr. James Foster, M.D is a Family Medicine healthcare provider based in Richmond, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275590218.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Foster, M.D has received a total of $29,307 in payments from pharmaceutical and medical device companies, with $4,790 received in 2024. These payments were reported across 1,068 transactions from 65 companies. The most common payment nature is "Food and Beverage" ($14,979).
As a Medicare-enrolled provider, Foster has provided services to 26,609 Medicare beneficiaries, totaling 39,751 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 231 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Richmond, VA
- Active Since 04/26/2006
- Last Updated 09/20/2011
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1275590218
Products in Payments
- FARXIGA (Drug) $1,010
- Vascepa (Drug) $791.69
- Ozempic (Drug) $786.99
- UBRELVY (Drug) $654.80
- XIFAXAN (Drug) $480.48
- NURTEC ODT (Drug) $417.70
- JARDIANCE (Drug) $386.31
- JANUVIA (Drug) $372.50
- XARELTO (Drug) $369.58
- QULIPTA (Drug) $346.84
- TRULICITY (Drug) $328.96
- EVENITY (Biological) $319.86
- TRINTELLIX (Drug) $313.69
- ELIQUIS (Drug) $278.47
- Rybelsus (Drug) $265.41
- Aimovig (Biological) $248.17
- ENTRESTO (Drug) $244.95
- TRELEGY ELLIPTA (Drug) $223.72
- Victoza (Drug) $223.27
- NEXLETOL (Drug) $223.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Richmond
Jan Diamond, Md, MD
Family Medicine — Payments: $226,571
Edwin Robinson, Md, MD
Family Medicine — Payments: $144,986
Dr. Ivan Mefford, Md, MD
Family Medicine — Payments: $117,040
Dr. Paul Stairs, Md, MD
Family Medicine — Payments: $84,850
Mary Gauthier, M.d, M.D
Family Medicine — Payments: $30,050
Dr. Carlos Munoz, M.d, M.D
Family Medicine — Payments: $22,690